Louisiana Just Limited What Its Licensing Boards Can Do About Peptides. Federal Law Did Not Move an Inch

On August 1, 2026, Louisiana Act 374 took effect and told the state's professional and occupational licensing boards what they may no longer prohibit. Boards cannot bar a provider with prescriptive authority from giving patients peptides, and cannot bar a Louisiana pharmacist from compounding and dispensing them, so long as the product comes through a compliant federal pathway. Within days the practical reading circulating in the industry was that Louisiana had legalized peptides. It did not. It removed one layer of state discipline and left the layer that actually sends people to prison exactly where it was.

Read the statute's own conditions. The safe harbor exists only where the peptide comes from an FDA-registered 503B outsourcing facility complying with 21 U.S.C. § 353b, or a 503A pharmacy complying with 21 U.S.C. § 353a and the applicable USP-NF chapters. Louisiana wrote its protection in the language of federal compounding law. That means the moment a provider steps outside those pathways, the state protection evaporates and the only law left standing is the law that carries criminal penalties.

Act 374 restrains Louisiana licensing boards. It does not restrain the Department of Justice, and it wrote its own protection in the language of federal compounding law.

Key Takeaways

• Louisiana Act 374, effective August 1, 2026, limits licensing board restrictions on peptides but creates no defense to federal charges under 21 U.S.C. §§ 331 and 333.
• The Act's protection applies only to peptides sourced through 503A or 503B pathways under 21 U.S.C. §§ 353a and 353b. Research-grade product is outside it entirely.
• Marketing a state law as permission to sell peptides is how a compliance question becomes a wire fraud case under 18 U.S.C. § 1343.
• Florida has enacted no Act 374 analogue, and telehealth prescribing into Louisiana from a Florida clinic remains subject to both states' rules plus federal law.
• The Southern District of Florida is among the most active federal districts for peptide, GLP-1, and med spa prosecutions in the country.

What Act 374 Actually Does

Act 374 began as Senate Bill 253 in the 2026 Regular Session, was signed by Governor Jeff Landry on May 22, 2026, and became effective August 1, 2026. It added R.S. 37:23.5 to the Louisiana revised statutes. The enacted text is narrow and it is worth being precise about the boundaries, because the gap between what the law says and what people believe it says is where clients get hurt.

The statute's safe harbor turns entirely on sourcing. 503A, 503B, and the applicable USP-NF chapters are the conditions, and the paperwork on the bench is what proves them.

The law restrains boards. It does not grant authority. A provider who lacked prescriptive authority on July 31 still lacks it today. A pharmacist who was not compounding within 503A limits before is not now permitted to do so. What changed is that a Louisiana board may not treat compliant peptide activity as a disciplinable act. That is a real and useful change for licensees who were operating in a gray zone under threat of board action. It is not a change in the criminal law, and Louisiana could not have made one if it wanted to.

Where the Government Is Looking

Federal peptide enforcement has settled into a recognizable shape over the last eighteen months, and it is not built around state licensing at all. FDA's Office of Criminal Investigations works these cases with DOJ, and the entry point is almost always product sourcing rather than clinical judgment.

The pattern runs like this. Investigators identify a supplier, often an importer or a domestic reseller moving material labeled for research use only. They pull the customer list. The customer list is a list of clinics, and each clinic becomes a potential defendant or a potential witness depending on how early it gets counsel and what its records show. A recent federal case involving imported peptide and GLP-1 products distributed as unapproved drugs in Michigan followed that structure. So did the sentencing of a peptide seller earlier this year. The clinic owners who were surprised were the ones who thought the supplier's paperwork was their protection.

"Every additional Louisiana clinic that adds a peptide line this quarter is another name on a distributor's ledger."— Aaron M. Cohen, AMC Defense Law

Act 374 changes nothing about that pipeline. If anything it raises the risk in the near term, because a statute that reads like permission generates volume, and volume generates records.

Exposure and Charges

The core exposure is the Food, Drug, and Cosmetic Act. Introducing an unapproved new drug into interstate commerce, or a misbranded drug, violates 21 U.S.C. § 331, with penalties at 21 U.S.C. § 333. A first offense without intent to defraud is a misdemeanor. With intent to defraud or mislead, it is a felony carrying up to three years per count. Prosecutors rarely stop there.

Wire fraud under 18 U.S.C. § 1343 is the count that changes the math. Twenty years per count, no federal payer required, and the wires are the clinic's own website, its intake portal, and its payment processing. A practice that told patients its peptides were FDA-approved, or that Louisiana law made them lawful without qualification, has created the misrepresentation. Where two or more people ran it together, 18 U.S.C. § 1349 charges the owner, the medical director, and the management entity as a conspiracy with the same maximum.

Referral arrangements with prescribing physicians can trigger the Anti-Kickback Statute at 42 U.S.C. § 1320a-7b, and an HHS-OIG subpoena is usually the first visible sign of that theory.

Loss calculation under USSG § 2B1.1 is where sentences are actually built. In peptide cases the government typically argues gross receipts from the product line as loss, which turns a modest practice into a double-digit offense level adjustment before any enhancement for number of victims or sophisticated means.

The Mistakes That Make It Worse

Treating a favorable state statute as legal advice. Act 374 has a defined scope written in federal terms. A provider who reads the headline and not the conditions has adopted a compliance position no one vetted. If that position is wrong, the fact that it was sincerely held is a jury argument, not a shield.

Talking to the investigator. FDA inspectors, board investigators, and federal agents all collect statements from owners who believe an explanation will end the inquiry. Those statements are permanent, and an inaccurate one is a separate felony under 18 U.S.C. § 1001.

The government's first grand jury request will reach years of purchase records, marketing, and patient files. Negotiating that scope early protects material that has no business being in a grand jury.

Cleaning up the file. Sourcing records reconstructed after an inquiry opens are obstruction under 18 U.S.C. § 1519, which carries twenty years and converts a defensible sourcing dispute into a case that cannot be defended.

Waiting. These investigations run quietly for one to three years. A federal target letter is the end of the phase where the outcome was still open, not the beginning of the case.

How This Gets Defended

The work that changes outcomes happens before charges. A pre-indictment defense lawyer can establish whether the client is a witness, a subject, or a target, open a controlled channel with the agents and the line prosecutor, and put the practice's own sourcing reconstruction in front of the government before it commits to a theory. In peptide matters that reconstruction is usually the whole case. Invoices, 503A and 503B documentation, USP-NF compliance records, and the chain from manufacturer to clinic either establish good faith or they do not.

Act 374 is genuinely useful here, not as a defense to the charge, but as evidence of what a reasonable Louisiana provider understood the law to permit in August 2026. That is a good faith argument and it should be preserved contemporaneously, in writing, with dates.

Federal grand jury subpoena defense in this space is largely about scope. The government's first request will reach years of purchase records, marketing, and patient files. Negotiating that scope early protects material that has no business being in a grand jury.

Why the Timing Matters Now

Charging decisions are fluid early and rigid late. Before indictment a prosecutor can decline, divert, or narrow. After indictment every path runs through a courtroom.

There is a second clock specific to this statute. Act 374 took effect six weeks ago. Louisiana boards have issued no interpretive guidance. The FDA has not acted on the PCAC recommendations for the seven peptide bulk substances. Practices are making sourcing decisions right now, in writing, that will be read back to them later against whatever the rules turn out to be. The documentation created in this window is the documentation that decides these cases.

Common Questions

Facing a Peptide, GLP-1, or Compounded Drug Investigation?

AMC Defense Law represents physicians, nurse practitioners, physician assistants, pharmacy principals, med spa owners, and platform operators in federal investigations, state licensing matters, and criminal prosecutions involving peptide sourcing, compounded drug distribution, scope of practice, and marketing conduct. Our South Florida federal criminal defense practice is based in Boca Raton and handles matters throughout Florida and nationwide. If an inspector, an agent, a subpoena, or a target letter has reached your practice, speak with a federal criminal defense attorney before you respond.

If you or your loved ones have been arrested or are under federal investigation, call Aaron M. Cohen, 24 hours a day to get help.

Pre-indictment defense is where peptide matters are decided. The sourcing reconstruction goes in front of the government before it commits to a theory, not after.